Henan Cancer Hospital and Baiji Shenzhou strategic cooperation, complementary resources to improve the level of cancer diagnosis and treatment

(Health Times reporter Qiu Yue)
October 28, Henan Cancer Hospital and Baiji Shenzhou 2020 strategic cooperation launch and signing ceremony was held in Zhengzhou. The two sides announced that they will carry out all-round in-depth cooperation in clinical research and other aspects, while training high-quality clinical research personnel, improve the level of clinical trial research in China, accelerate the transformation of basic research results into clinical applications, and promote the development of China's biopharmaceutical industry.Wu Xiaobin, president of Baiji Shenzhou Company, and Zhang Jiangon, party secretary and president of Henan Cancer Hospital, signed a contract
Zhang Jianggong, president of Henan Cancer Hospital, said that the hospital to "promote clinical research in all aspects" as a development strategy, after more than 40 years of hard work, is now in a "clinical hospital" to "clinical research hospital" transformation and development of the key period. Today, "hospital-enterprise cooperation" is the only way to accelerate the organic integration of upstream and downstream resources in the pharmaceutical industry and achieve their own sustainable development. Henan Cancer Hospital and Baiji Shenzhou reached a strategic cooperation, will fully mobilize their respective advantages of resources, promote the 'production, learning, research, use' integration of construction, in order to enhance China's ability to develop new drugs.
Wu Xiaobin, president of Baiji Shenzhou Company, said that Henan Cancer Hospital has outstanding medical and clinical research capabilities, and looks forward to working together to contribute to the development of China's new drug creation through in-depth cooperation between the two sides, bringing hope to more patients and bringing more "China programs" to the world.
In accordance with the strategic cooperation agreement, the two sides adhere to the principle of "complementary advantages, win-win cooperation", focusing on drug research and development to clinical verification transformation, tumor marker research to clinical individual diagnosis and treatment transformation and other fields, actively carry out medical and pharmaceutical collaborative innovation and research results transformation applications, explore the construction of basic research in the field of oncology, clinical research, clinical transformation, industrial development of the four-in-one strategic cooperation model, further promote the sharing of resources between the two sides, accelerate the development and clinical application of innovative drugs in China and even the world as soon as possible.